Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Monotherapy versus combination therapy for overactive bladder
PACTR202601758391175Phase 4Recruiting
- Sponsor
- Minia Urology and Nephrology University Hospital
- Start
- Aug 2024
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of solifenacin and mirabegron in overactive bladder (OAB) (3 arms), sponsored by Minia Urology and Nephrology University Hospital. Primary endpoint: Efficacy comparison at 3 months. Started Aug 2024; status: recruiting.
02
Drugs
solifenacinmirabegron
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on PACTR202601758391175.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202601758391175.